

Connecting via Winsock to STN

Welcome to STN International' Enter x:x

LOGINID:sssptal635jxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 CDS will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 00 FORGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 22 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 04 CANCERLIT reload  
NEWS 17 Aug 04 PHARMAMarketLetter (PHARMANL) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 20 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAFIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
  
NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:46:32 ON 25 SEP 2002

=> FIL BIOSIS SCISEARCH CA MEDLINE USPATFULL  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.42	0.42

FILE 'BIOSIS' ENTERED AT 09:47:32 ON 25 SEP 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'SCISEARCH' ENTERED AT 09:47:32 ON 25 SEP 2002  
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'CA' ENTERED AT 09:47:32 ON 25 SEP 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:47:32 ON 25 SEP 2002

FILE 'USEFUL.L' ENTERED AT 09:47:32 ON 25 SEP 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

```

=> s (phospholip? (2n) scramble? (2n) 1) or plscr1 or hmmtralb
L1      55 (PHOSPHOLIP? (2N) SCFAMBL? (2N) 1) OF PLSCR1 OR HMMTRALB

```

```
=> s antisense or (complement? (2n) oligonucle?)
L2 103714 ANTISENSE OR. (COMPLEMENT? (2N) OLIGONUCLE?)
```

=> s l1 and l2  
L3                    & L1 AND L2

```
=> dup rem 13
PROCESSING COMPLETED FOR L3
L4          7 DUP REM L3 (2 DUPLICATES REMOVED)
```

```
=> d 14 1-7 ikib absd
'ABSD' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUILE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT): ikib abs
```

L4 ANSWER 1 OF 7 USPATFULL  
 ACCESSION NUMBER: 2002:157099 USPATFULL  
 TITLE: 326C1, novel human phospholipid scramblase-like  
 molecules and uses thereof  
 INVENTOR(S): Glucksmann, Maria Alexandra, Lexington, MA, UNITED  
 STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002081698	A1	20020627
APPLICATION INFO.:	US 2001-795036	A1	20010226 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-180234P	20000229 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH  
TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000  
NUMBER OF CLAIMS: 22  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Page(s)  
LINE COUNT: 4168  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel human phospholipid scramblase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length human phospholipid scramblase-like proteins, the invention further provides isolated human phospholipid scramblase-like fusion proteins, antigenic peptides, and anti-human phospholipid scramblase-like antibodies. The invention also provides human phospholipid scramblase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a human phospholipid scramblase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 7 USPATFULL

ACCESSION NUMBER: 2002:99407 USPATFULL  
TITLE: Nucleic acids, proteins and antibodies  
INVENTOR(S): Posen, Craig A., Laytonsville, MD, UNITED STATES  
Fuben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052308	A1	20020502
APPLICATION INFO.:	US 2001-925301	A1	20010810 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-US5882, filed on 8 Mar 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124270P	19990312 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	30577	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presense of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The

present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 7 USPATFULL

ACCESSION NUMBER: 2002:72597 USPATFULL  
TITLE: Compositions, kits, and methods for identification and modulation of T helper-1 and T helper-2 cells and diseases associated therewith  
INVENTOR(S): Hanrahan, Catherine F., London, UNITED KINGDOM  
Feldmann, Marc, London, UNITED KINGDOM  
Trepicchio, William L., Andover, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002039734	A1	20020404
APPLICATION INFO.:	US 2001-860655	A1	20010517 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205204P	20000518 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	5319	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions, kits and methods for identifying, detecting, and modulating the differentiation, growth, and/or maturation of Th1 or Th2 cells. The invention further relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating a Th1- or Th2-associated condition. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of a Th1 or Th2 cell or Th1- or Th2-associated condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 7 USPATFULL

ACCESSION NUMBER: 2002:65885 USPATFULL  
TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis  
INVENTOR(S): Trepicchio, William L., Andover, MA, UNITED STATES  
Oestreicher, Judith L., Portsmouth, NH, UNITED STATES  
Dorner, Andrew J., Lexington, MA, UNITED STATES  
Krueger, James G., New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037538	A1	20020328
APPLICATION INFO.:	US 2001-852400	A1	20010509 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-203087P	20000509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	47	

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 12 Drawing Page(s)  
LINE COUNT: 6087  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating psoriasis. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of psoriasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 7 BICSI3 COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 1  
ACCESSION NUMBER: 2002:317709 BIOSIS  
DOCUMENT NUMBER: PFEVL00200317709  
TITLE: Role of MmTPAlb/phospholipid scramblase1 gene expression in

the induction of differentiation of human myeloid leukemia cells into granulocytes.

AUTHOR(S): Nakamaki, Tsuyoshi; Okabe-Kado, Junko; Yamamoto-Yamaguchi, Yuri; Hino, Ken-ichiro; Tomoyasu, Shigeru; Honma, Yoshio; Kasukabe, Takashi (1)

CORPORATE SOURCE: (1) Saitama Cancer Center Research Institute, 818 Komuro, Ina, Saitama, 362-0806: kasukabe@cancer-c.pref.saitama.jp Japan

SOURCE: Experimental Hematology (Charlottesville), (May, 2002) Vol. 30, No. 5, pp. 421-429. <http://www.iseh.org/journal/>. print.  
ISSN: 0301-472X.

DOCUMENT TYPE: Article

LANGUAGE: English

AB Objective. We previously cloned a human normal counterpart (MmTRAlb/**phospholipid scramblase 1**) of the mouse leukemogenesis-associated gene MmTRAla. MmTPAlb gene expression was increased during differentiation of human monoclastic leukemia U937 cells using some differentiation inducers but not  $\alpha$ ,25-dihydroxyvitamin D3 (a typical monocytic differentiation inducer). To further elucidate the role of human MmTRAlb gene expression in the differentiation of myelogenous leukemia cells, we measured MmTPAlb gene expression in several myeloid leukemia cell lines and primary leukemia cells. Materials and Methods. The expression of MmTRAlb mRNA was determined by semiquantitative reverse transcriptase polymerase chain reaction. Results. Expression of the MmTPAlb gene was markedly induced during granulocytic differentiation of promyelocytic leukemia NB4 and HT93 cells induced by all-trans retinoic acid (ATRA). The level of MmTPAlb mRNA was significantly increased during differentiation toward granulocytes, but not monocytes/macrophages, in bipotential myeloid leukemia HL-60 cells. The level of MmTRAl mRNA was not increased during erythroid differentiation induced by hemin in erythroid leukemia K562 and HEL cells or during megakaryocytic differentiation induced by 12-O-tetradecanoylphorbol-13-acetate in K562 cells. Expression of the MmTPAlb gene also was not induced when apoptosis of NB4 cells was induced by antileukemic drugs. ATRA-induced differentiation of **antisense** MmTPAlb-transfected NB4 cells was significantly suppressed. On the other hand, ATRA induced the differentiation of MmTRAlb-transfected NB4 cells more efficiently than that of mock-transfected cells. MmTPAlb mRNA also was clearly induced in ATRA-treated primary acute promyelocytic leukemia cells during granulocytic differentiation. Conclusion. MmTRAlb mRNA was specifically induced during granulocytic differentiation of acute promyelocytic leukemia cells and was associated with induction of their differentiation.

L4 ANSWER 6 OF 7 USPTAFULL

ACCESSION NUMBER: 2001:40250 USPTAFULL

TITLE: Methods and compositions to alter the cell surface expression of phosphatidylserine and other

INVENTOR(S): clot-promoting plasma membrane phospholipids  
Wiedmer, Therese, Mequon, WI, United States  
PATENT ASSIGNEE(S): Sims, Peter J., Mequon, WI, United States  
The Blood Center Research Foundation, Milwaukee, WI,  
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6204035	B1	20010320
APPLICATION INFO.:	US 1997-949245		19971010 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-790186, filed on 29 Jan 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Sisson, Bradley L.		
ASSISTANT EXAMINER:	Longton, Enrique D.		
LEGAL REPRESENTATIVE:	Quarles & Brady		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	2158		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A protein preparation that mediates Ca.sup.+2 transbilayer movement of phospholipid is disclosed. Additionally, a modified or mutated protein preparation, wherein the protein has a reduced ability to mediate transbilayer movement, is disclosed. In a preferred form of the invention, the protein has been modified such that post-translational modification can no longer occur.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 7 USPATFULL

ACCESSION NUMBER: 2001:4884 USPATFULL  
TITLE: DNA encoding phospholipid scramblase  
INVENTOR(S): Wiedmer, Therese, Mequon, WI, United States  
Sims, Peter J., Mequon, WI, United States  
PATENT ASSIGNEE(S): Blood Center Research Foundation, Milwaukee, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172210	B1	20010109
APPLICATION INFO.:	US 1997-790186		19970129 (8)
DOCUMENT TYPE:	Patent		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hendricks, Keith D.		
LEGAL REPRESENTATIVE:	Quarles & Brady LLP		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	2		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1372		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An protein preparation that mediates Ca.sup.+2 transbilayer movement of phospholipid is disclosed. A recombinantly engineered DNA sequence encoding the protein, an inhibitor of the protein activity, genetically engineered cells with altered protein activity, and therapeutic methods are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

30.04

30.46

STN INTERNATIONAL LOGOFF AT 09:50:27 ON 25 SEP 2002